TCT 497: FANTOM II Long Lesion Study: Initial Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold in Long Lesions – 4 Clinical Year Outcomes

Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:

• Consultant Fee/Honoraria/Speaker’s Bureau - Abbott Vascular; REVA Medical; AstraZenca; CardiacDimensions